Quanterix (QTRX) Scheduled to Post Earnings on Tuesday

Share on StockTwits

Quanterix (NASDAQ:QTRX) is scheduled to be releasing its Q2 2019 earnings data before the market opens on Tuesday, August 6th. Analysts expect Quanterix to post earnings of ($0.43) per share for the quarter.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). The business had revenue of $12.34 million for the quarter, compared to analyst estimates of $11.33 million. Quanterix had a negative return on equity of 76.62% and a negative net margin of 79.48%. On average, analysts expect Quanterix to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

QTRX stock opened at $31.05 on Monday. The firm has a market capitalization of $773.15 million, a price-to-earnings ratio of -21.71 and a beta of 1.25. The company has a current ratio of 3.10, a quick ratio of 2.64 and a debt-to-equity ratio of 0.22. Quanterix has a 12-month low of $13.00 and a 12-month high of $36.15. The firm has a fifty day moving average price of $32.26.

In other Quanterix news, SVP David C. Duffy sold 1,277 shares of Quanterix stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $20.78, for a total value of $26,536.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman E Kevin Hrusovsky sold 3,145 shares of Quanterix stock in a transaction on Monday, July 1st. The shares were sold at an average price of $34.64, for a total transaction of $108,942.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,727 shares of company stock worth $458,958. 30.80% of the stock is owned by company insiders.

Several equities analysts recently issued reports on the stock. Canaccord Genuity restated a “buy” rating and issued a $38.00 target price on shares of Quanterix in a report on Wednesday, July 24th. Zacks Investment Research lowered shares of Quanterix from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.

Recommended Story: Bear Market

Earnings History for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Set $12.25 Target Price for Cumberland Pharmaceuticals, Inc.
Zacks: Analysts Set $12.25 Target Price for Cumberland Pharmaceuticals, Inc.
Short Interest in Webster Financial Co.  Grows By 20.3%
Short Interest in Webster Financial Co. Grows By 20.3%
WESCO International, Inc.  Short Interest Down 16.4% in July
WESCO International, Inc. Short Interest Down 16.4% in July
Advance Auto Parts  Stock Rating Reaffirmed by Evercore ISI
Advance Auto Parts Stock Rating Reaffirmed by Evercore ISI
AAC  Lowered to “Market Perform” at Raymond James
AAC Lowered to “Market Perform” at Raymond James
SSE  Given Neutral Rating at JPMorgan Chase & Co.
SSE Given Neutral Rating at JPMorgan Chase & Co.


© 2006-2019 Ticker Report